Anaesthesiology and Intensive Care, Medical University of Innsbruck, Innsbruck, Austria.
Anaesthesiology and Intensive Care, Medical University of Innsbruck, Innsbruck, Austria
Reg Anesth Pain Med. 2023 Oct;48(10):508-512. doi: 10.1136/rapm-2023-104398. Epub 2023 Mar 16.
The addition of adjuvants to short-acting local anesthetics (LA) is common practice in clinical routine to speed up block onset and decrease pain on injection. In a previous study, we observed the development of microscopic crystal precipitations after bupivacaine or ropivacaine were mixed with adjuvants; this follow-up study is intended to clarify whether crystallization (A) also occurs in short-acting or intermediate-acting LA-adjuvant mixtures, (B) changes over time, and (C) is associated with the solutions' pH.
Lidocaine 2%, prilocaine 2%, mepivacaine 2%, procaine 2% and chloroprocaine 2% were individually mixed with clonidine, dexamethasone, dexmedetomidine, epinephrine, fentanyl, morphine or sodium bicarbonate 8.4% in clinically established ratios. For each mixture, we measured initial pH and recorded crystallization patterns at 0, 15, 30 and 60 min using a standardized, semiquantitative light microscopy approach.
Lidocaine 2% and mepivacaine 2% plus sodium bicarbonate 8.4%, and mepivacaine 2% plus dexamethasone developed delayed grade 5 crystallization over 1 hour. Prilocaine-based, procaine-based and chloroprocaine-based mixtures showed much less pronounced crystallization, with a maximum of grade 2. Initial pH and grade of crystallization showed weak monotonic relationships at time points t, t and t (ρ=-0.17, 0.31 and 0.32, (all p>0.05)) and a moderate relationship time point t (ρ=0.57 (p=0.0003)) CONCLUSIONS: Our study revealed high grades of crystallization in lidocaine/mepivacaine-bicarbonate and mepivacaine-dexamethasone mixtures, although these were previously considered safe for local, perineural or neuraxial use. Our findings cast particular doubt on the safety of preparing these formulations for later use.
在临床常规中,将佐剂添加到短效局部麻醉剂(LA)中是很常见的做法,以加快阻滞起效并减少注射疼痛。在之前的一项研究中,我们观察到布比卡因或罗哌卡因与佐剂混合后会出现微观晶体沉淀;本后续研究旨在阐明(A)结晶是否也发生在短效或中效 LA-佐剂混合物中,(B)随时间的变化,以及(C)是否与溶液的 pH 值有关。
将利多卡因 2%、丙胺卡因 2%、甲哌卡因 2%、普鲁卡因 2%和氯普鲁卡因 2%分别与可乐定、地塞米松、右美托咪定、肾上腺素、芬太尼、吗啡或碳酸氢钠 8.4% 以临床既定比例混合。对于每种混合物,我们测量初始 pH 值,并使用标准化的半定量光镜方法在 0、15、30 和 60 分钟时记录结晶模式。
利多卡因 2% 和碳酸氢钠 8.4% 与利多卡因 2% 加地塞米松混合后出现延迟 1 小时的 5 级结晶;丙胺卡因、普鲁卡因和氯普鲁卡因混合物结晶程度较轻,最大为 2 级。初始 pH 值和结晶程度在时间点 t、t 和 t 时显示出微弱的单调关系(ρ=-0.17、0.31 和 0.32,(均 p>0.05)),在时间点 t 时显示出中度关系(ρ=0.57(p=0.0003))。
我们的研究显示利多卡因/甲哌卡因-碳酸氢盐和甲哌卡因-地塞米松混合物结晶程度较高,尽管这些药物以前被认为可安全用于局部、周围神经或脊神经阻滞。我们的发现尤其怀疑为以后使用而制备这些制剂的安全性。